How Natriuretic Peptides Diagnose and Guide Heart Failure Treatment: A Global Expert Consensus
Three major international heart failure societies jointly affirm natriuretic peptides (BNP and NT-proBNP) as essential tools for diagnosing heart failure, predicting outcomes, and guiding treatment — including their growing role as therapeutic targets through ARNI drugs.
Quick Facts
What This Study Found
This trilateral scientific statement from the European, American, and Japanese heart failure societies provides a comprehensive framework for how natriuretic peptides — specifically BNP and NT-proBNP — should be used in diagnosing and managing heart failure. The document covers four major areas: the biology and cardiovascular protective effects of natriuretic peptides; their established role as diagnostic and prognostic biomarkers in both acute and chronic heart failure; their use as endpoints in clinical trials and as guides for therapy adjustment; and their direct therapeutic applications through drugs like nesiritide (recombinant BNP), carperitide (ANP), and ARNIs (sacubitril/valsartan).
The statement emphasizes that with the development of ARNIs — which work by preventing the breakdown of natriuretic peptides — these peptides have gained importance not just as biomarkers but as therapeutic agents in their own right.
Key Numbers
Consensus from 3 international societies · Covers BNP + NT-proBNP · 4 focus areas: biology, biomarkers, therapy, future directions · 28 expert authors
How They Did This
Expert consensus scientific statement developed through the Trilateral Cooperation Project among the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America, and Japanese Heart Failure Society. Synthesizes existing evidence across diagnosis, prognosis, clinical trials, and therapeutics.
Why This Research Matters
Natriuretic peptides are the single most important blood test in heart failure diagnosis. This consensus statement from three major international societies represents the authoritative global perspective on how to use them — from initial diagnosis to guiding treatment decisions. The emergence of ARNI therapy (sacubitril/valsartan) has transformed natriuretic peptides from passive biomarkers into active therapeutic targets, making this framework especially relevant.
The Bigger Picture
Natriuretic peptides are arguably the most clinically successful peptide biomarkers in medicine. This consensus statement captures a pivotal moment: these peptides are no longer just diagnostic tools — they're now treatment targets. ARNI therapy works by blocking the enzyme that destroys natriuretic peptides, effectively boosting the body's own cardioprotective peptide system. This dual role as biomarker and therapeutic target is unique in cardiovascular medicine.
What This Study Doesn't Tell Us
As a consensus statement rather than a systematic review, it reflects expert opinion and may be subject to selection bias in evidence cited. Clinical practice recommendations may vary by region and healthcare system. Rapidly evolving therapeutics may outpace some recommendations.
Questions This Raises
- ?Can natriuretic peptide-guided therapy reliably improve outcomes compared to standard clinical management across all heart failure subtypes?
- ?Will newer natriuretic peptide-enhancing therapies beyond ARNIs emerge, and how will they change the diagnostic landscape?
- ?How should BNP versus NT-proBNP testing be standardized globally for consistent clinical decision-making?
Trust & Context
- Key Stat:
- 3 major societies, 1 unified framework The European, American, and Japanese heart failure societies jointly created this comprehensive guide — the first trilateral consensus on how natriuretic peptides should be used across the full spectrum of heart failure care.
- Evidence Grade:
- Rated high: expert consensus statement from three major international cardiology societies, synthesizing decades of clinical evidence. While not a systematic review, it represents the highest level of authoritative clinical guidance in the field.
- Study Age:
- Published in 2023. This is a current and authoritative document reflecting the latest evidence on natriuretic peptide use in heart failure, including the impact of ARNI therapy.
- Original Title:
- Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
- Published In:
- Journal of cardiac failure, 29(5), 787-804 (2023)
- Authors:
- Tsutsui, Hiroyuki(2), Albert, Nancy M(2), Coats, Andrew J S(3), Anker, Stefan D, Bayes-Genis, Antoni, Butler, Javed, Chioncel, Ovidiu, Defilippi, Christopher R, Drazner, Mark H, Felker, G Michael, Filippatos, Gerasimos, Fiuzat, Mona, Ide, Tomomi, Januzzi, James L, Kinugawa, Koichiro, Kuwahara, Koichiro, Matsue, Yuya, Mentz, Robert J, Metra, Marco, Pandey, Ambarish, Rosano, Giuseppe, Saito, Yoshihiko, Sakata, Yasushi, Sato, Naoki, Seferovic, Petar M, Teerlink, John, Yamamoto, Kazuhiro, Yoshimura, Michihiro
- Database ID:
- RPEP-07478
Evidence Hierarchy
Frequently Asked Questions
What are natriuretic peptides and why do doctors test for them?
BNP and NT-proBNP are peptides released by your heart when it's under stress or working too hard. A simple blood test measuring these levels helps doctors diagnose heart failure, assess its severity, and monitor whether treatment is working. Higher levels generally mean the heart is under more strain.
How have natriuretic peptides gone from blood tests to treatment targets?
ARNI drugs like sacubitril/valsartan work by blocking neprilysin, the enzyme that breaks down natriuretic peptides. This effectively boosts your body's own cardioprotective peptide system, turning natriuretic peptides from passive diagnostic markers into active players in treatment.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-07478APA
Tsutsui, Hiroyuki; Albert, Nancy M; Coats, Andrew J S; Anker, Stefan D; Bayes-Genis, Antoni; Butler, Javed; Chioncel, Ovidiu; Defilippi, Christopher R; Drazner, Mark H; Felker, G Michael; Filippatos, Gerasimos; Fiuzat, Mona; Ide, Tomomi; Januzzi, James L; Kinugawa, Koichiro; Kuwahara, Koichiro; Matsue, Yuya; Mentz, Robert J; Metra, Marco; Pandey, Ambarish; Rosano, Giuseppe; Saito, Yoshihiko; Sakata, Yasushi; Sato, Naoki; Seferovic, Petar M; Teerlink, John; Yamamoto, Kazuhiro; Yoshimura, Michihiro. (2023). Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.. Journal of cardiac failure, 29(5), 787-804. https://doi.org/10.1016/j.cardfail.2023.02.009
MLA
Tsutsui, Hiroyuki, et al. "Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.." Journal of cardiac failure, 2023. https://doi.org/10.1016/j.cardfail.2023.02.009
RethinkPeptides
RethinkPeptides Research Database. "Natriuretic Peptides: Role in the Diagnosis and Management o..." RPEP-07478. Retrieved from https://rethinkpeptides.com/research/tsutsui-2023-natriuretic-peptides-role-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.